As shown in Figure 3A, subjects with IGF2 hypermethylation (15.54%), compared to subjects with IGF2 hypomethylation (84.46%), had a significantly increased CRC risk (PS-adjusted OR, 2.57, 95% CI: 1.64-4.03; P<0.001). The gene discussed is IGF2; the disease is colorectal carcinoma.